SCHEMBL27199332

SCHEMBL27199332

COc1c(Cl)ncc2cnn(CC(F)(F)F)c12

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HSP90AA1 P07900 1/20 0.34
TRAP1 Q12931 1/20 0.34
NPBWR1 P48145 4/20 0.33
HSD17B10 Q99714 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HTT P42858 1/20 0.33
CYP17A1 P05093 1/20 0.32
CYP1A2 P05177 1/20 0.32
MAPK1 P28482 1/20 0.32
P2RX7 Q99572 1/20 0.31
KDM4E B2RXH2 2/20 0.31
MAP3K12 Q12852 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
USP1 O94782 4/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30498388 1.00 HTR2A (0.34) HTR2AHTR2CHSP90AA1TRAP1NPBWR1
SCHEMBL25758951 0.90 LRRK2 (0.34) HTR2AHTR2CHSP90AA1TRAP1NPBWR1
SCHEMBL27199574 0.87 USP1 (0.33) HTR2AHTR2CHSP90AA1TRAP1NPBWR1
SCHEMBL30498313 0.87 USP1 (0.33) HTR2AHTR2CHSP90AA1TRAP1NPBWR1
SCHEMBL25758167 0.85 HTR2A (0.35) HTR2AHTR2CHSP90AA1TRAP1NPBWR1
SCHEMBL30498058 0.82 MAP3K12 (0.35) HTR2AHTR2CHSP90AA1TRAP1HSD17B10
SCHEMBL25758418 0.82 MAP3K12 (0.35) HTR2AHTR2CHSP90AA1TRAP1HSD17B10
SCHEMBL23994486 0.78 P2RX7 (0.33) HTR2AHTR2CCYP17A1CYP1A2P2RX7
SCHEMBL31359710 0.76 DGAT1 (0.34) HTR2AHTR2CHSP90AA1TRAP1
SCHEMBL30498325 0.75 HTR2A (0.41) HTR2AHTR2CHSD17B10ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 HTR2A 3276/4885HTR2C 3809/4885HSP90AA1 2667/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 HTR2A 3276/4885HTR2C 3809/4885HSP90AA1 2667/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 HTR2A 3276/4885HTR2C 3809/4885HSP90AA1 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.